Nordic Myeloma Study Group
10
1
3
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
30%
3 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Role: collaborator
Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
Role: collaborator
Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients
Role: collaborator
REST - Replacing Steroids in the Transplant Ineligble
Role: collaborator
Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support
Role: collaborator
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
Role: lead
Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients
Role: lead
Bortezomib and High-dose Melphalan at Myeloma Relapse
Role: lead
Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
Role: lead
Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients
Role: lead
All 10 trials loaded